fasudil + diethylenetriamine nonoate

Fasudil + diethylenetriamine nonoate is an investigational combination therapy being developed by Vascular BioSciences (VBS Pharmaceuticals) for the treatment of pulmonary arterial hypertension (PAH) and COVID-19. The formulation co-delivers fasudil, a Rho-kinase (ROCK) inhibitor, and diethylenetriamine NONOate (DETA NONOate), a long-acting nitric oxide (NO) donor, within CAR peptide-modified liposomes. The CAR peptide (CARSKNKDC) is a cyclic 9-amino-acid homing peptide that selectively targets diseased pulmonary vasculature, allowing for localized delivery via inhalation. This dual-pathway approach aims to reduce vasoconstriction and vascular remodeling by inhibiting RhoA/ROCK signaling while simultaneously promoting vasodilation through nitric oxide donation. Preclinical studies have demonstrated significant reductions in pulmonary arterial pressure and amelioration of vascular remodeling features.

Other names

Fasudil + DETA NONOate liposomesCAR-targeted liposomal combination therapypeptide-modified liposomes